As­traZeneca says mon­o­clon­al an­ti­body com­bo is 77% ef­fec­tive at pre­vent­ing Covid-19

Af­ter hit­ting just about every pot­hole with its Covid-19 vac­cine roll­out, As­traZeneca has some good news to share for an­oth­er pan­dem­ic-re­lat­ed pro­gram: Its mon­o­clon­al an­ti­body com­bo, AZD7442, proved ef­fec­tive at pre­vent­ing symp­to­matic Covid-19 in a Phase III study.

AZD7442 re­duced the risk of symp­to­matic Covid-19 by 77%, based on a pre­lim­i­nary group of cas­es in a large, glob­al Phase III tri­al, ac­cord­ing to the British phar­ma. The study, dubbed PROVENT, en­rolled near­ly 5,200 vol­un­teers across the US, UK, Spain, France and Bel­gium, 75% of whom had co­mor­bidi­ties or con­di­tions that would cause a re­duced im­mune re­sponse to vac­ci­na­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER